T
Terufumi Kato
Researcher at University of Texas Health Science Center at San Antonio
Publications - 70
Citations - 8344
Terufumi Kato is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 17 publications receiving 6626 citations. Previous affiliations of Terufumi Kato include Kanagawa Prefectural Hospital & April.
Papers
More filters
Journal ArticleDOI
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist,James Chih-Hsin Yang,Nobuyuki Yamamoto,Kenneth J. O'Byrne,Vera Hirsh,Tony Mok,Sarayut Lucien Geater,Sergey Orlov,Chun-Ming Tsai,Michael Boyer,Wu Chou Su,Jaafar Bennouna,Terufumi Kato,Vera Gorbunova,Ki Hyeong Lee,Riyaz Shah,Dan Massey,Victoria Zazulina,Mehdi Shahidi,Martin Schuler +19 more
TL;DR: The LUX-Lung 3 study as mentioned in this paper investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epIDERmal growth factors receptor 2 (HER2/ERbB2), and ErbbB4 and has wide-spectrum preclinical activity against EGFR mutations.
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
Lecia V. Sequist,James Chih-Hsin Yang,Nobuyuki Yamamoto,Kenneth J. O'Byrne,Vera Hirsh,Tony Mok,Sarayut Lucien Geater,Sergey Orlov,Chun-Ming Tsai,Michael Boyer,Wu Chou Su,Jaafar Bennouna,Terufumi Kato,Vera Gorbunova,Ki Hyeong Lee,Riyaz Shah,Dan Massey,Victoria Zazulina,Mehdi Shahidi,Martin Schuler +19 more
TL;DR: Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.
Journal ArticleDOI
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang,Yi-Long Wu,Martin Schuler,Martin Sebastian,Sanjay Popat,Nobuyuki Yamamoto,Caicun Zhou,Cheng Ping Hu,Kenneth J. O'Byrne,Jifeng Feng,Shun Lu,Yunchao Huang,Sarayut Lucien Geater,Kye Young Lee,Chun-Ming Tsai,Vera Gorbunova,Vera Hirsh,Jaafar Bennouna,S. M. Orlov,Tony Mok,Michael Boyer,Wu Chou Su,Ki Hyeong Lee,Terufumi Kato,Dan Massey,Mehdi Shahidi,Victoria Zazulina,Lecia V. Sequist +27 more
TL;DR: In this article, the effect of Afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials was evaluated.
Journal ArticleDOI
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Takashi Seto,Terufumi Kato,Makoto Nishio,Koichi Goto,Shinji Atagi,Yukio Hosomi,Noboru Yamamoto,Toyoaki Hida,Makoto Maemondo,Kazuhiko Nakagawa,Seisuke Nagase,Isamu Okamoto,Takeharu Yamanaka,Kosei Tajima,Ryosuke Harada,Masahiro Fukuoka,Nobuyuki Yamamoto +16 more
TL;DR: Erlotinib plus bevacizumab combination could be a new first-line regimen in EGFR mutation-positive NSCLC and serious adverse events occurred at a similar frequency in both groups.
Journal ArticleDOI
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik,E. Felip,Remi Veillon,Hiroshi Sakai,Alexis B. Cortot,Marina Chiara Garassino,J. Mazieres,Santiago Viteri,Hélène Senellart,Jan van Meerbeeck,Jo Raskin,Niels Reinmuth,Pierfranco Conte,Dariusz M. Kowalski,Byoung Chul Cho,Jyoti D. Patel,Leora Horn,Frank Griesinger,Ji Youn Han,Young Chul Kim,Gee Chen Chang,Chen Liang Tsai,James Chih-Hsin Yang,Yuh Min Chen,Egbert F. Smit,Anthonie J. van der Wekken,Terufumi Kato,Dilafruz Juraeva,Christopher Stroh,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,J. Heymach,Xiuning Le +34 more
TL;DR: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients, and adverse events led to permanent discontinuation of tEPotinib in 11% of the patients.